Breadcrumb Home People Principal Investigators Aviv Regev, Ph.D. Director, Ó³»´«Ã½ of MIT and Harvard, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Regev Lab Nir Hacohen Co-director, Ó³»´«Ã½ of MIT and Harvard, Massachusetts General Hospital, Harvard Medical School Co-Principal Investigators Bradley E. Bernstein, M.D., Ph.D. Ó³»´«Ã½ of MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Howard Hughes Medical Institute, Alexander Meissner, Ph.D. Harvard University, Ó³»´«Ã½ of MIT and Harvard, Paul Blainey, Ph.D. Ó³»´«Ã½ of MIT and Harvard, Massachusetts Institute of Technology, Alex K. Shalek, Ph.D. Massachusetts Institute of Technology, Ó³»´«Ã½ of MIT and Harvard, Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Nir Friedman, Ph.D. The Hebrew University of Jerusalem, Feng Zhang Ó³»´«Ã½ of MIT and Harvard, McGovern Institute for Brain Research, Massachusetts Institute of Technology, Staff Elliot Boblitt Project Manager, Regev Lab, Ó³»´«Ã½ Center for Cell Circuits About Outreach Computational Genomics Workshop People Publications Latest news News 11.03.2025 Biology of Adversity Project launches at Ó³»´«Ã½ News 10.31.2025 Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Ó³»´«Ã½ for chimeric antigen receptor (CAR) T-cell therapy News 10.31.2025 Genetic variant increases risk of heart muscle disease common in individuals of African ancestry News 10.16.2025 Ó³»´«Ã½-Bayer collaboration leads to drug candidate for a hard-to-treat type of lung cancer All news
News 10.31.2025 Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Ó³»´«Ã½ for chimeric antigen receptor (CAR) T-cell therapy
News 10.31.2025 Genetic variant increases risk of heart muscle disease common in individuals of African ancestry
News 10.16.2025 Ó³»´«Ã½-Bayer collaboration leads to drug candidate for a hard-to-treat type of lung cancer